Brown, Lisle/Cummings’s Adaptive Biotechnologies ADPT Stock Holding History

Brown, Lisle/Cummings’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200	Closed	-$2.99K	–	743
2025 Q3	$2.99K	Hold	200	–	–	﹤0.01%	614
2025 Q2	$2.33K	Hold	200	–	–	﹤0.01%	642
2025 Q1	$1.49K	Hold	200	–	–	﹤0.01%	673
2024 Q4	$1.2K	Hold	200	–	–	﹤0.01%	619
2024 Q3	$1.02K	Hold	200	–	–	﹤0.01%	598
2024 Q2	$724	Hold	200	–	–	﹤0.01%	594
2024 Q1	$642	Hold	200	–	–	﹤0.01%	548
2023 Q4	$980	Hold	200	–	–	﹤0.01%	555
2023 Q3	$1.09K	Sell	200 -600	-75%	-$3.97K	﹤0.01%	530
2023 Q2	$5.37K	Hold	800	–	–	﹤0.01%	471
2023 Q1	$7.06K	Buy	800 +600	+300%	+$5.29K	﹤0.01%	430
2022 Q4	$1.53K	Hold	200	–	–	﹤0.01%	490
2022 Q3	$1.42K	Hold	200	–	–	﹤0.01%	482
2022 Q2	$1.62K	Hold	200	–	–	﹤0.01%	455
2022 Q1	$2.78K	Hold	200	–	–	﹤0.01%	450
2021 Q4	$5.61K	Buy	+200	New	+$6.13K	﹤0.01%	408

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brown, Lisle/Cummings's ADPT Position: Q4 2025 in Review

Brown, Lisle/Cummings sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 200 shares — an estimated $2.99K sold.

Brown, Lisle/Cummings first reported a position in ADPT in Q4 2021 and held it in 16 quarters. The position peaked at $7.06K in Q1 2023. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

Brown, Lisle/Cummings reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
Brown, Lisle/Cummings sold 200 Adaptive Biotechnologies shares in Q4 2025, an estimated $2.99K.
Brown, Lisle/Cummings first reported a position in Adaptive Biotechnologies in Q4 2021 and held it in 16 quarters.
Brown, Lisle/Cummings's Adaptive Biotechnologies position peaked at $7.06K in Q1 2023.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Brown, Lisle/Cummings's 13F filing for Q4 2025, filed 23 Jan 2026.